Q-omics provides the consensus-scored DCAF10 profile across patient tissues and cancer cell-line models. DCAF10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, DCAF10 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, DCAF10 protein abundance shows 29,147 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, THCA, and GBM as cancer lineages where DCAF10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF10 survival associations across molecular data types. DCAF10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF10 RNA expression–survival associations across cancer types. High DCAF10 expression shows unfavorable associations in CESC, ACC, UVM and MESO, but favorable associations in BRCA and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for DCAF10 RNA expression.
This table summarizes DCAF10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DCAF10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF10 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC, HNSC, BRCA and COAD. The THCA box plot shows higher DCAF10 RNA expression in normal versus tumor tissue (log2 FC = −0.552, t-test p < 0.001).
This table shows molecular features associated with DCAF10 in patient tissues and cancer cell lines. In patient samples, DCAF10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAF10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
